The primary bactericidal domain of CAP37, a cationic antimicrobial protein with potent activity against Gram-negative organisms was previously shown to reside between amino acids 20 through 44 (NQGRHFCGGALIHARFVMTAASCFQ) of the native protein. In this study, we explored the effi cacy of four synthetic CAP37 peptide analogs, based on this sequence, against various Candida species including fl uconazole-sensitive and -resistant isolates of C . albicans. Three of the peptides demonstrated strong antifungal activity for C. albicans , including fl uconazole-resistant isolates of C. albicans and were active against C. guilliermondii , C. tropicalis , C. pseudotropicalis , C. parapsilosis , and C. dubliniensis . The peptides were ineffective against C. glabrata , C. krusei, and Saccharomyces cerevisiae . For C. albicans isolates, the peptides had relatively greater activity against blastoconidia than hyphal forms, although strong antifungal activity was observed with pseudohyphal forms of the various Candida species tested. Kinetic studies demonstrated fungicidal rather than fungistatic activity. These fi ndings indicate that synthetic peptides based on the antimicrobial domain of CAP37 also have activity against eukaryotic organisms suggesting a broader range of activity than originally demonstrated and show for the fi rst time their potent fungicidal activity. [ 10, 11 ], and smooth muscle cell functions [ 12 ]. Structure function analysis of CAP37 enabled us to ascribe its antibacterial activity to a domain consisting of 25 amino acids corresponding to residues 20 through 44 of the native molecule [ 13 ]. A synthetic peptide (CAP37 20-44 ) based on this sequence mimicked the antimicrobial activity of the native molecule [ 13 ] and demonstrated an extended range of activity to encompass two Gram-positive organisms, Staphylococcus aureus and Enterococcus faecalis .
Introduction
CAP37 (cationic antimicrobial protein of M r 37 kDa), also termed heparin binding protein [ 1 ] and azurocidin [ 2 ] , was originally identifi ed as a component of the oxygenindependent killing mechanism of the human neutrophil (PMN) and demonstrated strong bactericidal activity for
In vivo experiments demonstrated the effi cacy of CAP37 in attenuating the lethal effects of E. coli lipopolysaccharide (LPS) in a rat model of endotoxic shock [ 14 ] . The synthetic peptide bound and neutralized the toxic effects of LPS resulting in the attenuation of many of the circulatory and metabolic dysfunctions and lethality associated with sepsis [ 14 ] . The combination of sequence, charge, amphipathicity and hydrophobicity appear to be unique to CAP37 , since two synthetic peptides, based on cathepsin G and neutrophil elastase, share almost 40% sequence identity in this region and were signifi cantly less effective at killing bacteria and binding LPS [ 13, 14 ] .
In this study we extended our fi ndings on the antimicrobial repertoire of the synthetic peptide CAP37 to determine whether it possessed antifungal activity as a means to evaluate its effects against eukaryotes. We further explored the importance of the cysteine residues by synthesizing two new analogs of CAP37 . One analog had the cysteine at position 26, substituted with a serine residue (CAP37 ), and the other had the cysteine at position 42 replaced with a serine residue (CAP37 ). The activities of these three analogs were compared to a fourth peptide in which both cysteine residues were replaced by serine residues (CAP37 20-44ser26/42 ). The latter peptide had previously been shown to be ineffective against Gramnegative organisms [ 13 ] . The various CAP37 peptide analogs were tested for activity against fl uconazole-sensitive and -resistant clinical isolates of Candida albicans , a number of other Candida species and two isolates of Saccharomyces cerevisiae to determine their range of activity . Additionally, the effi cacy of the peptide on hyphal forms of C. albicans and pseudohyphal forms of C. pseudotropicalis and C. tropicalis was determined along with a series of time-kill studies to establish whether the activity was fungicidal or fungistatic.
Materials and methods

Synthesis of peptides based on CAP37
Peptides were synthesized by tert-butyloxycarbonyl (Boc)/ benzyl solid-phase synthesis on an Applied Biosystems peptide synthesizer (model 433A, Foster City, CA) as previously described [ 6 ] . PAM-resins were used and activation of Boc-amino acids was accomplished using HOBt/DCC. The side-chain-protected, Boc-L-amino acids included: BocArg(mesitylsulfonyl); Boc-Cys(4-methoxybenzyl) for Cys; Boc-His(dinitrophenyl), Boc-His(benzyloxycarbonyl) or Boc-His(benzoxymethyl) for His; Boc-Ser(benzyl); and BocThr(benzyl). The couplings were performed in either dimethylformamide or N-methylpyrrrolidone/dimethyl sulfoxide as solvents. The peptides were cleaved off the resin and deprotected in liquid HF/anisole/dimethyl sulfi de (10:1:0.5) for 1 h at 0°C, precipitated with cold diethyl ether, extracted into 50% aqueous acetic acid, and lyophilized. The crude peptides were dissolved in formic acid/TFA/trifl uoroethanol/water (20:1:10:70, v/v) at approximately 15 mg/ml and purifi ed by preparative reversed-phase (RP) HPLC on a Zorbax SB-C18 silica column (22 ϫ 250 mm, 5 μm particle size, 300 A pore size; Agilent, Palo Alto, CA) equilibrated in 0.1% aqueous TFA and eluted using a linear gradient of acetonitrile in 0.08% aqueous TFA at 25°C. Purity of the peptides was ascertained by analytical RP-HPLC using a C18 silica SUPER-ODS column (2.1ϫ100 mm, 2 μm particle size, 300 A pore size; TosoHaas, Montgomeryville, PA), eluted using a gradient of acetonitrile in 0.1% aqueous TFA and monitored at 214 nm. It confi rmed our observations made during preparative RP-HPLC, namely that CAP37 20-44 and its derivatives aggregate in highly acidic solutions and do not chromatograph as sharp, distinct peaks on C18 packings; instead they elute as broad peaks in the 40% and 50% acetonitrile concentration range. Counter-ion alternatives to TFA, such as heptafl uorobutyric acid or formic acid, and/or alternative elution solvents to acetonitrile, such as 2-propanol or 1-butanol, did not improve the elution profi les of these peptides, and neither did column elution at higher temperatures (up to 65°C). The HPLC fractions were screened by MALDI-TOF mass spectrometry (MS) and those containing the desired product, as determined by its presence as the major base peak in the mass spectra corresponding to the desired product, were pooled. The purifi ed peptides were obtained lyophilized in the form of their TFA salts. The purity and integrity of the peptides was confi rmed by MALDI-TOF MS and electrospray ionization MS, and by N-terminal Edman sequencing, using described protocols [ 15 ] .
Peptides were synthesized predicated on previous fi ndings that a synthetic peptide, CAP37 , based on the native amino acid sequence of CAP37 consisting of residues 20 through 44 (NQGRHFCGGALIHARFVMTAASCFQ) had potent bactericidal activity for a number of Gramnegative organisms [ 13 ] . CAP37 20-44 contains two cysteine residues in positions 26 and 42 which form a disulfi de bridge in the native CAP37 molecule [ 16 ] . Previously we showed that simultaneous replacement of both cysteines with serine residues (CAP37 20-44ser26/42 ) abrogated antibacterial activity [ 13 ] . This peptide is routinely incorporated in our in vitro studies to serve as an inactive or control peptide. The synthesis of CAP37 20-44 is technically challenging due to problems related to solubility and aggregation in the purifi cation stage. We thus queried whether a peptide with replacement of a single cysteine would retain its antimicrobial activity yet overcome the purifi cation problems we had encountered. Therefore, in this study, we synthesized two new analogs containing singly substituted cysteine residues. The analog in which the cysteine at position 26 was replaced by a serine is indicated as CAP37 20-44ser26 and the analog in which the cysteine at position 42 was replaced by a serine is indicated as CAP37 20-44ser42 . The replacement of either one or both cysteine residues is considered a very conservative replacement [ 17 ] . The peptides used in this study were obtained with cysteine residues in their reduced form. We confi rmed, using mass spectrometry that under the conditions used for the assay (pH 5.5, see below) no signifi cant oxidation of the peptides occurred in the stock solutions prior to their use or upon several weeks of storage at Ϫ20°C.
Fungal isolates and culture conditions
Isolates used in this study included C . albicans (3153A), three fl uconazole-sensitive isolates of C. albicans and three fl uconazole-resistant isolates of C. albicans from patients with vulvovaginitis; and a blood isolate of C. albicans obtained from a patient with candidemia. Isolates were stored frozen at Ϫ70°C in 10% glycerol and streaked onto Sabouraud Dextrose Agar (SAB, Sigma, St. Louis, MO) plates and maintained on plates at 4°C, with subculturing approximately every 10 days for the duration of the studies. Fluconazole resistance as determined by standard in vitro susceptibility assays was defi ned as the MIC of Ͼ64 μg/ml. Three clinical isolates of C. glabrata ; two clinical isolates of C. dubliniensis ; single isolates each of C. krusei, C. guilliermondii, C. parapsilosis, C. pseudotropicalis , and C. tropicalis ; and two isolates of Saccharomyces cerevisiae were also used in this study and were maintained similarly on SAB plates at 4°C. For use in assays, a single yeast colony was cultured at 33°C in 1% phytone peptone broth (Becton Dickinson, Sparks, MD) with 0.1% D-glucose (Sigma) to stationary phase (∼18 h or overnight). Blastoconidia were collected and enumerated by trypan blue dye exclusion.
Induction of hyphae
To induce hyphal formation, a single colony of each C. albicans isolate was cultured as above to stationary phase. An aliquot (500 μl) of the stationary phase culture was subcultured in 5 ml of RPMI-1640 (Cellgro Mediatech Inc, Herndon, VA) with 10% fetal calf serum (Invitrogen, Grand Island, NY) for 120 min at 37°C with rotation. Cultures were monitored and assessed for hyphal formation using phase microscopy. The C. albicans isolates under these growth conditions were predominantly mycelium but with some still in transition from germ tube to hyphae [ 18 ] . C. pseudotropicalis and C. tropicalis demonstrated pseudohyphal morphology under the growth conditions described. Samples were normalized by optical density reading at 600 nm for addition to the antifungal assays as described below. Enumeration of samples was confi rmed by plating100 μl of the culture at the start of the assay (T ϭ 0).
Standard antifungal colony forming unit (CFU) assay
A standard CFU assay [ 2 ,4 ,13 ] was performed to assess the antifungal activity of the peptides incorporating the following modifi cations. Stock solutions (1mg/ml) of all peptides were made in sterile endotoxin-free water for irrigation (Baxter, Deerfi eld, IL). Subsequent dilutions were all made in tryptone saline pH 5.5 [ 3 ] . An aliquot (100 μl) of a stationary phase fungal culture was subcultured further in 5 ml of 1% phytone peptone broth with 0.1% glucose and incubated in a shaking water bath (80 oscillations per min, Precision, Winchester, VA) for 90 min at 33°C to yield a logarithmic culture. Cell cultures under these conditions were found to consist predominantly of blastoconidia as determined by phase contrast microscopy. The optical density was determined and the culture adjusted to 500 blastoconidia/100 μl in tryptone saline pH 5.5 [ 3 ] . To 100 μl of the organism suspension in a 96 well sterile polystyrene microtiter plate (Becton Dickinson, Franklin Lakes, NJ) was added 100 μl of the peptide at varying concentrations for an initial dose response and further at fi nal concentrations of 400 μg/ml and 200 μg/ml. In addition, two controls, T ϭ 0 and T ϭ 240, were set up consisting of 100 μl of organism suspension and 100 μl of tryptone saline. 100 μl from the T ϭ 0 control was plated immediately and served to confi rm the starting numbers of the organisms used in each assay. The microtiter plate was incubated at 37°C for 4 h and 100 μl of the contents from each well was plated on SAB plates and incubated at 37°C overnight. The CFU were counted and the antifungal activity was expressed as percent inhibition and calculated according to the following equation: [(T 240 control CFU Ϫ test CFU)/T 240 control CFU]ϫ100 ϭ % inhibition. T 240 control CFU was an indication of the number of colonies present following 240 min of incubation in tryptone saline alone in the absence of peptide. Test CFU was determined by counting the number of colonies present after incubation in tryptone saline containing the peptide. Each experimental point was performed in triplicate. Assays were conducted on blastoconidia unless otherwise indicated.
Time-kill assays
Kinetic fungicidal assays were performed using C.albicans (3153A), C. pseudotropicalis , C. glabrata , and S. cerevisiae . CAP37 20-44 and control peptide, CAP37 20-44ser26/42 at concentrations ranging from 400 to 100 μg/ml were incubated with the four isolates listed above for 2, 5, 15, 30, 60 and 240 min and cell death measured using the standard antifungal CFU assay.
Statistical analysis
Data are presented as meanϮstandard error from three or four independent experiments. Statistical analysis of the data was performed employing one-way analysis isolates of Candida tested ( P Ͻ 0.001). CAP37 and CAP37 20-44ser42 were highly effective against C. guilliermondii and C. parapsilosis at concentrations as low as 100 μg/ml (37.5 μM) ( Fig. 2 ) compared to control peptide ( P Ͻ 0.001). C. pseudotropicalis , was also extremely sensitive to peptides CAP37 20-44 , CAP37 20-44ser26 , and CAP37 20-44ser42 compared to the control peptide ( P Ͻ 0.001). Surprisingly, some activity, although signifi cantly less than with the other three peptides, was also obtained against C. pseudotropicalis with the control peptide CAP37 20-44ser26/42 , considered as ineffective against Gram-negative organisms. CAP37 20-44ser26/42 lacked activity (% inhibition Յ40%) against all other Candida species and S. cerevisiae isolates tested. C. tropicalis , C. albicans , and C. dubliniensis were also sensitive to CAP37 20-44 , CAP37 20-44ser26 and CAP37 20-44ser42 ( P Ͻ 0.001 compared to CAP37 20-44ser26/42 ). Similar to C. guilliermondii and C. pseudotropicalis , there was no signifi cant difference between the activity of the three active peptides for C. tropicalis and C. albicans . However, CAP37 20-44 was signifi cantly less active than CAP37 20-44ser26 and CAP37 20-44ser42 against C. parapsilosis ( P Ͻ 0.001) and the two isolates of C. dubliniensis ( P Ͻ 0.01 and 0.001). Activity against the three C. glabrata isolates, the single isolate of C. krusei , and the two isolates of S. cerevisiae , was considered minimal to negative when compared to the activity of the peptides against all the other isolates tested.
Antifungal activity of CAP37 peptides on fl uconazole-sensitive and -resistant isolates of C. albicans
Having established the activity of the CAP37 peptides against the panel of Candida species, we next evaluated their antifungal activity against three fl uconazole-sensitive and three fl uconazole-resistant clinical mucosal isolates of C. albicans. We found that the peptides CAP37 
Results
Standardization of in vitro CFU assay
C. albicans (3153A) was used to initiate and standardize the in vitro antifungal assay. We explored a range of peptide concentrations (750, 500, 400, 200 and 100 μg/ ml), contact time between peptide and Candida (0.5 1, 2, and 4 h), optimal growth conditions to achieve log phase cultures of Candida (temperature and time, 25°C for 5 h and 33°C for 90 min), and numbers of blastoconidia per well (200, 400, 500, 600, 800, and 1000 CFU) in the standard 4 h assay. Peptides are considered inactive at inhibition of Ͻ40%. Results in Fig. 1 , depict a dose response analysis using 500 CFU C. albicans and a 4 h incubation time with peptide. There was good distinction between the activities of the active (CAP37 ) and the control peptide (CAP37 20-44ser26/42 ) at 400, 200, and 100 μg/ml. We selected peptide concentrations of 400 (150 μM) and 200 μg/ml (75 μM) for our standard assay. We selected 4 h as the routine time of exposure of Candida to the peptides based on fi ndings that the inactive peptide required 120 to 240 min to reach maximum activity. These data are fully discussed in the detailed time-kill studies described later in the results section and are not duplicated here. Data (not shown) indicated that there was no signifi cant difference between Candida that had been cultured for 5 h at 25°C or for 90 min at 33°C. The 90 minute incubation was more convenient technically and was therefore employed routinely. Analysis of the number of blastoconidia per well indicated that 500 CFU was optimal. The standard assay thus consisted of using 500 CFU per well of Candida that had been grown to log phase at 33°C for 90 minutes and incubated for 4 h at 37°C with peptides at concentrations of 400 and 200 μg/ml. Any variations from these standard conditions are indicated in the relevant fi gure legends.
Antifungal activity of CAP37 peptides on various Candida species
Using the standard CFU assay, we analyzed all four peptides for their antifungal activity on a number of different species of Candida and two isolates of S. cerevisiae . Differential activity of the CAP37 peptides was observed depending on the species of Candida tested ( Fig. 2 ) . CAP37 , and CAP37 20-44ser42 were signifi cantly more active than CAP37 20-44ser26/42 on all exhibiting approximately 58% inhibition. There were no signifi cant differences in antifungal activity between each of the three active peptides for any of the fl uconazole-resistant isolates.
Antifungal activity of CAP37 peptides on hyphal forms of C. albicans
To determine whether CAP37 peptides could inhibit hyphal growth, we evaluated the activity against the same fl uconazolesensitive and -resistant C. albicans isolates following conditions for hyphal development ( Fig. 4 a-f ). Of the various CAP37 peptides tested, CAP37 20-44ser42 was signifi cantly inhibitory against hyphal forms of all 6 isolates tested, when compared with the control peptide, CAP37 20-44ser26/42 ( P Ͻ 0.05 with isolate in Fig. 4 a, and P Ͻ 0.01 with all other isolates). CAP37 20-44 was signifi cantly inhibitory against the hyphal form of isolates in 
Antifungal activity of CAP37 peptides on pseudohyphal forms of C. pseudotropicalis and C. tropicalis
In contrast to the limited activity displayed by the CAP37 peptides against the hyphal forms of C. albicans, against the fl uconazole-sensitive isolates ( Fig. 3 a-c) at a concentration of 400 μg/ml (Ϫ150 μM) when compared to the activity demonstrated by the control peptide CAP37 20-44Ser26/42 ( P Ͻ 0.001). There was no statistical difference ( P Ͼ 0.05), as determined by ANOVA followed by Tukey's Multiple Comparison Test, between the activities of the three peptides (CAP37 ) at 400 μg/ml for any given fl uconazolesensitive isolate. Furthermore, there was no statistical difference ( P Ͼ 0.05) in the activity of each peptide for the three different fl uconazole-sensitive isolates. Activity was negligible with CAP37 and CAP37 20-44ser42 at 200 μg/ml. The antifungal activity of peptides CAP37 20-44 , CAP37 against the three fl uconazole-resistant isolates of C. albicans are shown in Fig. 3 d-f . Peptides CAP37 , and CAP37 20-44Ser42 were highly active against the three fl uconazole-resistant isolates compared with peptide CAP37 20-44ser26/42 ( P Ͻ 0.05 with isolate in Figure 3 d and P Ͻ 0.001 with isolates in Fig. 3 e & f) . Signifi cant activity ( P Ͻ 0.05) was also obtained with the lower concentration (200 μg/ml or 75 μM) of peptides, CAP37 , with the fl uconazoleresistant isolate in Fig. 3 d . Although, peptide at 400 μg/ml was considerably less active than the other peptides with this isolate, it demonstrated moderate activity (Ser  42) , and CAP37 20-44Ser26/42 (Ser 26/42) was evaluated using a panel of Candida species that included C. guilliermondii , C. parapsilosis , C. pseudotropicalis , C. tropicalis , a blood isolate of C. albicans, two isolates of C. dubliniensis , three isolates of C. glabrata , one isolate of C krusei and two isolates of S. cerevisiae . Data reported here are for a single concentration of the four different peptides. The peptide concentration for C. guilliermondii and C. parapsilosis was 100 μg/ml (37.5 μM) whereas data for all other isolates were obtained using peptide concentrations of 400 μg/ml (150 μM). Values are expressed as Wstandard error of the mean from three to four independent experiments performed in triplicate. Statistical analysis of data was performed using ANOVA followed by Tukey's Multiple Comparison Test., *** P Ͻ 0.001 represent signifi cance values between control peptide and other peptides for an individual isolate. ## P Ͻ 0.01 and ### P Ͻ 0.001 represent signifi cance values between CAP37 20-44 and peptides CAP37 20-44ser26 and CAP37 20-44ser42 for an individual isolate. activity were observed as early as two minutes ( Fig. 6 b) . In contrast, and as expected from data depicted in Fig. 2 , the activity of both peptides was negligible against C. glabrata ( Fig. 6 c) and S. cerevisiae ( Fig. 6 d ) at all time points tested.
Discussion
In this study, we demonstrate for the fi rst time that synthetic peptides based on the CAP37 molecule have strong activity against eukaryotic organisms. We had previously shown that the 25 amino acid peptide based on the native sequence had activity against a range of prokaryotic organisms [ 13 ] .
Here we describe the synthesis of two new CAP37-derived peptide analogs in which the cysteine residues at positions 26 or 42 were replaced by serine residues. Our fi ndings demonstrate signifi cant activity against several Candida species by the peptide based on the native sequence and the two new analogs. The replacement of both cysteines significantly abrogated activity suggesting that a single cysteine residue is needed for the antifungal activity of the peptides. The concentration of CAP37 peptides required to achieve antifungal activity is approximately twice that required for we observed potent activity against the pseudohyphal form of C. pseudotropicalis with peptides CAP37 20-44 , CAP37 20-44Ser42 , CAP37 20-44Ser26 , and CAP37 20-44ser26/42 at 400 and 200 μg/ml ( Fig. 5 a) and C. tropicalis ( Fig. 5 b) with all four peptides at 400 μg/ml. Limited activity was observed against C. tropicalis using 200 μg/ml ( Fig. 5 b) .
Time-kill studies
Kinetic assays were performed with three different Candida species and one isolate of S. cerevisiae using CAP37 20-44 at three concentrations (400, 200 and 100 μg/ml) and CAP37 20-44ser26/42 at two concentrations (400 and 200 μg/ml). Antifungal activity of CAP37 20-44 at 400 μg/ml for C. albicans ( Fig. 6 a) showed a dramatic increase between 2 and 15 min and reached a plateau of T85% between 30 and 60 minutes, reaching maximum antifungal activity thereafter. The lower concentration of CAP37 20-44 , showed lesser activity at the earlier time points, but displayed signifi cant activity after 240 minutes of incubation. Activity of CAP37 20-44 was signifi cantly quicker and greater than CAP37 20-44ser26/42 at the comparable concentration. The rapid antifungal activity of CAP37 20-44 was more pronounced on C. pseudotropicalis . Signifi cant levels of We had previously proposed that the bactericidal mechanism of CAP37 and its antimicrobial peptides on Gramnegative organisms was due to the specifi c binding to the lipid A component of the endotoxin molecule [ 13 ,14 ] . The putative target molecule on yeast cells that acts as the receptor for the CAP37 peptides is presently unknown. It is possible that charge, hydrophobicity, and other nonspecifi c factors alone may contribute to this binding. Alternatively, it is possible that there may be a specifi c binding activity against the Gram-negative species S. typhimurium , E. coli , and P. aeruginosa [13 ] , although we used the same number of CFU in both the antifungal and antibacterial assays. This range in activity is not uncommon amongst cationic antimicrobial peptides, which tend to have specifi city and greater potency towards certain bacterial species, fungi, parasites and/or viruses. Fungicidal activity on sensitive isolates was relatively rapid requiring between 5 to 240 minutes contact time depending on the organisms. Our data showed that the peptides exhibited potent activity against C. guilliermondii and C. parapsilosis at lower concentrations (37.5 μM) compared to that for the other species. C. parapsilosis is most often isolated from critically ill patients in intensive care units who typically have indwelling catheters and devices while undergoing treatment [ 20, 21 ] . Almost 100% of the starting inocula of C. pseudotropicalis and C. tropicalis were killed with peptide concentrations of 150 μM. C. tropicalis is being increasingly isolated from blood cultures of patients with leukemias, other neoplasias, and those in intensive care units [ 22 ] . Of the peptides, CAP37 20-44Ser42 and CAP37 20-44ser26 were more effective against C. dubliniensis than peptide CAP37 20-44 which was based on the native sequence. C. dubliniensis is a recently identifi ed species that is seldom found in healthy persons but tends to be found as the causative agent of oropharyngeal infections mainly in HIV-infected individuals [ 23 ] . The peptides were ineffective against C. glabrata , C. krusei and S. cerevisiae . C. glabrata and C. kruse i are isolated with increasing frequency from blood stream infections and C. krusei in particular appears to be associated with hematological malignancies [ 24 -26 ] .
Noteworthy were our fi ndings that CAP37 , and CAP37 20-44Ser42 peptides were very effective against the fl uconazole-resistant mucosal isolates. Overall, fl uconazoleresistant and -sensitive species were inhibited nearly equally by the peptides. These fi ndings are particularly pertinent to the recent emergence of fl uconazole-resistant isolates of C. albicans and other Candida species that will require treatment with new therapeutics with novel or alternative mechanisms of action [ 23, 27 ] . In addition to the important fi nding that CAP37 peptides had activity against fl uconazole-resistant mucosal isolates of C. albicans , the peptides showed impressive activity against pseudohyphae. On the other hand, activity of the peptides against the hyphal forms was modest compared to the respective blastoconidia forms. It is unclear whether the differences between pseudohyphae and hyphae are due to the morphological forms or the species. Obviously, further studies will be needed to answer this question. A critical fi nding was that the activity of the peptides on susceptible isolates was fungicidal rather fungistatic. This was shown both by kinetic studies as well as vital staining (data not shown). This is an important consideration if CAP37 peptides are to be pursued as potential therapeutics, since a number of current antifungal drugs are fungistatic and not fungicidal. Besides CAP37, several cationic antimicrobial proteins including the defensins, hCAP18/LL37, bactericidal permeability increasing protein (BPI), and lactoferrin [ 5 ,28, 29 ] are active against C. albicans [30 , 31 ] . Another well known candidacidal molecule is salivary histatin-5 [ 32, 33 ] which is active on C. albicans blastospores at a concentration of 15 μM [ 34 ] . In addition, synthetic peptides based on naturally site on yeast for CAP37. It has recently been demonstrated that salivary histatin-5 kills C. albicans through a process that requires binding to Ssa1/2 proteins on the cell surface [ 19 ] . Clearly the structure function analysis of this complex peptide and its mode of action on bacteria and fungi require further exploration.
